TABLE 2.

Median OS relative to the pattern and extent of intratumoral spread

Spread	No. of patients	No. of patients with metastatic disease	Median survival (mo)* Months (95% CI)	P value†
1	8 (22.2%)	1 (12.5%)	5.9 (3.6−7.2)	<.0001
2	9 (25.0%)	3 (33.3%)	7.1 (3.7−10.6)
3	12 (33.0%)	3 (25.0%)	14.1 (10.2−16.0)
4	7 (19.4%)	1 (14.3%)	32.0 (21.4−42.2)

Visual assessment of the completeness of therapy, in terms of the pattern and extent of intratumoral spread, using a 4-point scale, with 1 representing the least dispersed pattern and 4 representing a more complete pattern and extent of intratumoral spread. The score was based on 3 features: (1) the final visually assessed ultrasonographic 3dimensional extent (determined no earlier than 10 minutes after the last injection, at which point no further diffusion was detected), (2) pattern, and (3) homogeneity of intratumoral gemcitabine spread.

OS, Overall survival.

^*Value in parentheses is 95% confidence interval.

^†Log-rank test.